methyl 8-aminoquinoline-5-carboxylate | 1612247-58-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: methyl 8-aminoquinoline-5-carboxylate
• 英文别名: Methyl8-aminoquinoline-5-carboxylate
• CAS: 1612247-58-1
• 化学式: C₁₁H₁₀N₂O₂
• 分子量: 202.213
• InChiKey: XOBNRNVOGFOUGO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  65.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 8-aminoquinoline-5-carboxylate 在 sodium azide 、 水 、 溶剂黄146 、 原甲酸三乙酯 、 sodium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 4.5h， 生成 8-(1H-tetrazol-1-yl)quinoline-5-carboxylic acid
  参考文献：
  名称：

  [EN] INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL
  [FR] INHIBITEURS DU CANAL POTASSIQUE MÉDULLAIRE EXTÉRIEUR RÉNAL

  摘要：

  本发明提供了式（I）的化合物及其药用可接受的盐，这些化合物是ROMK（Kir1.1）通道的抑制剂。这些化合物可用作利尿剂和/或钠利尿剂，并用于治疗和预防包括高血压、心力衰竭以及与过多盐分和水分潴留有关的疾病等医疗条件。

  公开号：

  WO2014085210A1
• 作为产物：
  描述：

  8-硝基喹啉 在 tris(bipyridine)ruthenium(II) dichloride hexahydrate 、 potassium carbonate 、 甲烷 、 一水合肼 作用下， 以 1,4-二氧六环 、 甲醇 为溶剂， 反应 84.0h， 生成 methyl 8-aminoquinoline-5-carboxylate
  参考文献：
  名称：

  Visible Light-Promoted Photocatalytic C-5 Carboxylation of 8-Aminoquinoline Amides and Sulfonamides via a Single Electron Transfer Pathway

  摘要：

  An efficient photocatalytic method was developed for the remote C5-H bond carboxylation of 8-aminoquinoline amide and sulfonamide derivatives. This methodology uses in situ generated ^•CBr₃ radical as a carboxylation agent with alcohol and is further extended to a variety of arenes and heteroarenes to synthesize the desired carboxylated product in moderate-to-good yields. The reaction proceeding through a single electron transfer pathway was established by a control experiment, and a butylated hydroxytoluene-trapped aryl radical cation intermediate in high-resolution mass spectrometry was identified.

  DOI：

  10.1021/acs.joc.9b00942

文献信息

• Inhibitors of the Renal Outer Medullary Potassium Channel
  申请人：WALSH Shawn P.

  公开号：US20150299198A1

  公开（公告）日：2015-10-22

  The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention.

  本发明提供了I式化合物及其药学上可接受的盐，它们是ROMK（Kir1.1）通道的抑制剂。该化合物可用作利尿剂和/或钠利尿剂，以及用于治疗和预防包括高血压、心力衰竭和与过多盐和水潴留有关的医疗状况的药物。
• INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2925322A1

  公开（公告）日：2015-10-07
• US9777002B2
  申请人：——

  公开号：US9777002B2

  公开（公告）日：2017-10-03
• Visible Light-Promoted Photocatalytic C-5 Carboxylation of 8-Aminoquinoline Amides and Sulfonamides via a Single Electron Transfer Pathway
  作者：Chiranjit Sen、Tapan Sahoo、Harshvardhan Singh、Eringathodi Suresh、Subhash Chandra Ghosh

  DOI：10.1021/acs.joc.9b00942

  日期：2019.8.16

  An efficient photocatalytic method was developed for the remote C5-H bond carboxylation of 8-aminoquinoline amide and sulfonamide derivatives. This methodology uses in situ generated ^•CBr₃ radical as a carboxylation agent with alcohol and is further extended to a variety of arenes and heteroarenes to synthesize the desired carboxylated product in moderate-to-good yields. The reaction proceeding through a single electron transfer pathway was established by a control experiment, and a butylated hydroxytoluene-trapped aryl radical cation intermediate in high-resolution mass spectrometry was identified.
• [EN] INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL<br/>[FR] INHIBITEURS DU CANAL POTASSIQUE MÉDULLAIRE EXTÉRIEUR RÉNAL
  申请人：MERCK SHARP & DOHME

  公开号：WO2014085210A1

  公开（公告）日：2014-06-05

  The present invention provides compounds of Formula (I), and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention.

  本发明提供了式（I）的化合物及其药用可接受的盐，这些化合物是ROMK（Kir1.1）通道的抑制剂。这些化合物可用作利尿剂和/或钠利尿剂，并用于治疗和预防包括高血压、心力衰竭以及与过多盐分和水分潴留有关的疾病等医疗条件。